Sign Out
Drug-Drug Interactions: Use with other iron chelator: JADENU should not be combined with other iron chelator therapies as the safety and efficacy of such combinations has not been established.
Use with Aluminum Containing Antacid Preparations: The concomitant administration of JADENU and aluminum-containing antacid preparations has not been formally studied. Although deferasirox has a lower affinity for aluminum than for iron, JADENU should not be taken with aluminum-containing antacid preparations (see Warnings and Precautions).
Use with Agents Metabolised through CYP3A4: In a healthy volunteer study, the concomitant administration of deferasirox tablets for oral suspension and midazolam (a CYP3A4 substrate) resulted in a decrease of midazolam exposure by 17%. In the clinical setting, this effect may be more pronounced. Therefore, caution should be exercised when JADENU is combined with substances metabolised through CYP3A4 (e.g. cyclosporine, simvastatin, hormonal contraceptive agents), due to a possible decrease in efficacy.
Use with Agents Inducing UDP-glucuronosyltransferase (UGT) Metabolism: In a healthy volunteer study, the concomitant administration of deferasirox tablets for oral suspension at single dose of 30 mg/kg) and the potent UDP-glucuronosyltransferase (UGT) inducer rifampicin (repeated dose of 600 mg/day) resulted in a decrease of deferasirox exposure by 44% (90% CI: 37% - 51%). Therefore, the concomitant use of JADENU with potent UGT inducers (e.g. rifampicin, phenytoin, phenobarbital, ritonavir) may result in a decrease in JADENU efficacy. If JADENU and a potent UGT inducer are used concomitantly, increases in the dose of JADENU should be considered based on clinical response to therapy.
Use with Bile Acid Sequestrants: In a healthy volunteer study, the administration of cholestyramine after a single dose of deferasirox tablets for oral suspension resulted in a 45% decrease in deferasirox exposure (AUC).
Use with Agents Metabolized by CYP2C8: In a healthy volunteer study, the concomitant administration of deferasirox tablets for oral suspension at 30 mg/kg/day for 4 days) and the CYP2C8 substrate repaglinide (single dose of 0.5 mg) resulted in an increase in repaglinide AUC and Cmax by 131% and 62%, respectively. When JADENU and repaglinide are used concomitantly, careful monitoring of glucose levels should be performed. An interaction between JADENU and other CYP2C8 substrates like paclitaxel cannot be excluded.
Use with Agents Metabolized by CYP1A2: In a healthy volunteer study, the concomitant administration of deferasirox tablets for oral suspension (at a repeated dose of 30 mg/kg/day) and the CYP1A2 substrate theophylline (single dose of 120 mg) resulted in an increase in theophylline AUC by 84% (90% CI: 73% to 95%). The single dose Cmax was not affected, but an increase of theophylline Cmax is expected to occur with chronic dosing. When JADENU and theophylline are used concomitantly, monitoring of theophylline concentration and possible theophylline dose reduction should be considered. An interaction between JADENU and other CYP1A2 substrates such as clozapine and tizanidine may be possible.
Use with Digoxin: In healthy volunteers, deferasirox tablets for oral suspension had no effect on the pharmacokinetics of digoxin. The effect of digoxin on JADENU pharmacokinetics has not been studied.
Use with Vitamin C: The concomitant administration of JADENU and vitamin C has not been formally studied. Doses of vitamin C up to 200 mg were allowed in clinical studies without negative consequences. High doses of vitamin C should not be used.
Use with ulcerogenic potential drugs: Concomitant administration of JADENU with drugs that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, and use of JADENU in patients receiving anticoagulants may increase the risk of gastrointestinal irritation (see Warnings and Precautions).
Use with hydroxyurea: The interaction of JADENU with hydroxyurea has not been formally studied. No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.
Drug-Food Interactions: JADENU should be taken on an empty stomach or with a light meal, preferably at the same time each day.
Drug-Herb Interactions: Interactions with herbal products have not been established.
Drug-Laboratory Interactions: Interactions between deferasirox and gallium contrast media have not been studied. It is known that the results of gallium-67 imaging may be distorted by the iron chelator deferoxamine due to chelation of gallium-67. It is therefore recommended that JADENU therapy be interrupted at least five days before gallium-67 scintigraphy.
